Gentronix Secures R&D Award
News Apr 11, 2006
The purpose of the two-year grant is to assist small businesses initiate or develop new research programmes, and will provide Gentronix with two scientists, cell culture facilities, and supporting laboratory instrumentation at its Manchester Incubator Core Technology Facility premises.
Greenscreen GC, the company’s commercially available yeast-based assay, is already proving an early screening tool in the drug development process.
In particular the assay’s high specificity is demonstrated by the extremely low incidence of false positives compared to other available tests.
The SBRI grant will enable Gentronix to build on this early success, and research and develop additional assays using alternative cell lines.
The aim is to increase screening sensitivity so that no genetically toxic compounds are missed whilst retaining the high specificity required, ensuring potentially valuable lead compounds are not eliminated from further development.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE